ARPA-H Just Committed $144 Million to Treating Aging Itself — Here Is What the PROSPR Program Means for Health Research

Sometime in the next eighteen months, 200 healthy adults in their early sixties will begin swallowing an HIV drug — not because they have HIV, but because researchers at the University of Rochester believe it can silence ancient genetic sequences that wake up as we age and trick our immune systems into chronic, body-wide inflammation. If it works, the implications extend far beyond one clinical trial. It would mean that one of the fundamental drivers of age-related decline — from heart disease to dementia to frailty — can be switched off with a pill that already has FDA safety data behind it.

That trial is one of seven projects funded through ARPA-H's PROactive Solutions for Prolonging Resilience program, better known as PROSPR. Announced in February 2026 with a ceiling of $144 million over five years, PROSPR represents the largest coordinated federal investment in treating biological aging as a unified process rather than chasing individual diseases one at a time. (Granted News)

The program's ambition is matched by its structure: these are contracts, not grants, with funding contingent on hitting aggressive milestones. If a team stalls, the money stops. ARPA-H is betting big, but it's betting with a short leash.

Seven Teams, Five Drugs, One Radical Hypothesis

PROSPR's scientific premise challenges the entire architecture of modern medicine. Instead of developing treatments for Alzheimer's, then separate treatments for heart failure, then separate treatments for sarcopenia — the conventional approach that has consumed trillions of dollars over decades — PROSPR asks whether slowing the aging process itself could delay or prevent all of them simultaneously.

Program manager Andrew Brack assembled seven teams pursuing complementary angles on that question:

UT Health San Antonio's Barshop Institute received the program's largest award — up to $38 million — for a trial called VITAL-H (Validation and Intervention Testing for Aging, Longevity and Healthspan). The study will test three FDA-approved drugs head-to-head in adults aged 60 to 65: rapamycin, dapagliflozin (an SGLT2 inhibitor used for diabetes), and semaglutide (the active ingredient in Ozempic and Wegovy). Rather than measuring traditional disease biomarkers, the trial will assess "Intrinsic Capacity" — a composite score covering cognition, mobility, psychological function, vitality, and sensory abilities. The Barshop Institute is partnering with the San Antonio GRECC, the South Texas Veterans Health Care System, and a mobile clinical research clinic to reach participants who would never set foot in a university hospital.

Cambrian BioPharma landed up to $30.8 million to test a next-generation rapamycin analog. Rapamycin, originally an immunosuppressant used in organ transplants, has shown remarkable lifespan-extending effects in animal studies for over a decade. The problem has always been side effects at immunosuppressive doses. Cambrian's oral formulation selectively inhibits mTORC1 signaling — the metabolic pathway most strongly linked to aging — while sparing the mTORC2 pathway responsible for the worst side effects. If the selectivity holds in humans, it could resolve the central tension that has kept rapamycin derivatives out of mainstream longevity medicine.

Linnaeus Therapeutics received up to $22 million to test LNS8801, an oral activator of the G protein-coupled estrogen receptor (GPER). Originally developed as an oncology drug — more than 100 cancer patients have already received it — LNS8801 has shown unexpected cardiometabolic benefits that researchers now believe are mediated through aging pathways rather than cancer-specific mechanisms. Brown University is a key partner on the clinical work.

The University of Rochester also received up to $22 million for what may be PROSPR's most conceptually provocative project. Led by Vera Gorbunova and Andrei Seluanov, the team is targeting retrotransposons — parasitic DNA sequences that make up roughly 40 percent of the human genome. These sequences are normally silenced, but they become increasingly active with age. When they do, the immune system detects them as foreign (essentially mistaking the body's own DNA for a viral infection) and mounts an inflammatory response. The Rochester team will test Censavudine (TPN-101), an HIV reverse transcriptase inhibitor, on the theory that blocking the enzyme retrotransposons need to replicate will quiet the inflammatory cascade. The trial will enroll 200 adults aged 60 to 65 across three sites — Rochester, UConn Health, and the University of Texas Medical Branch — for 48 weeks of treatment.

Stanford University is taking a different approach: rather than testing a specific drug, its team is harmonizing large health datasets to create a validated healthspan score that all PROSPR teams can use. The project includes a one-year lifestyle intervention study designed to calibrate how much various interventions move the score.

Columbia University Mailman School of Public Health is focused on identifying intervention-responsive biomarkers — the molecular signals that change when aging is actually being slowed. This is critical infrastructure work. Without validated biomarkers, aging research is stuck measuring outcomes that take decades to manifest. Columbia's work could compress future trial timelines dramatically.

Apollo Alpha, a St. Petersburg-based biotech, rounds out the seven with a compound targeting energy metabolism, lipid metabolism, and inflammation simultaneously — three pillars of metabolic aging that typically require separate interventions.

Why Contracts, Not Grants

ARPA-H's decision to structure PROSPR as milestone-based contracts rather than traditional research grants is not bureaucratic trivia. It fundamentally changes the incentive structure.

Under a typical NIH R01 grant, a research team receives funding based on a proposed plan and reports progress at intervals. The funding continues as long as the work is proceeding in good faith, even if results are disappointing. This model protects researchers from the inherent uncertainty of basic science, but it also insulates them from urgency.

ARPA-H contracts work differently. Funding tranches are tied to specific, pre-defined milestones. Miss a milestone, and the next tranche doesn't arrive. This is the same structure DARPA has used for decades to drive rapid technology development in defense — and it's the structure that produced the internet, GPS, and mRNA vaccine platform technology.

For PROSPR, the milestone structure means that clinical trials are compressed to one to three years rather than the decade-plus timelines typical of NIH-funded aging research. Teams must demonstrate measurable progress on defined metrics, not just publish papers exploring mechanisms. The $144 million ceiling is a maximum; actual disbursement depends entirely on performance.

What This Means for the Longevity Sector

PROSPR's significance extends well beyond the seven funded teams. For the broader longevity and healthspan research community, three implications stand out.

Regulatory pathway signaling. By funding clinical trials of existing FDA-approved drugs for aging-related endpoints, ARPA-H is implicitly validating the concept that aging itself — not just age-related diseases — is a legitimate therapeutic target. This matters enormously for regulatory strategy. The FDA has historically resisted approving drugs for "aging" because aging is not classified as a disease. PROSPR's trials, if successful, could generate the clinical evidence needed to change that calculus. The VITAL-H trial's use of "Intrinsic Capacity" as a primary endpoint is particularly significant — it offers a composite, clinically meaningful measure that regulators could accept as a basis for approval.

Biomarker standardization. Columbia's biomarker work and Stanford's healthspan score project address the field's most critical bottleneck: the absence of validated, accepted measures of biological aging. Without these, every longevity trial is an island — results from one study can't be compared to another. If PROSPR produces consensus biomarkers, future clinical trials across the entire field become faster, cheaper, and more credible.

Private capital validation. ARPA-H's $144 million commitment signals to venture capital and pharmaceutical companies that the federal government considers longevity medicine a serious, fundable discipline. Cambrian BioPharma and Linnaeus Therapeutics — both private companies — received direct ARPA-H contracts, demonstrating that the agency is willing to fund commercial entities pursuing healthspan therapeutics. For startups in the longevity space seeking Series A or B funding, pointing to a federal contract from ARPA-H carries weight that no amount of mouse data can match.

How Health Researchers Should Respond

PROSPR's current cohort of seven teams is locked in. But the program's structure, and ARPA-H's broader posture, point to clear opportunities for researchers and organizations working in adjacent spaces.

Monitor the biomarker and healthspan score outputs from Columbia and Stanford. When those frameworks are published, they will become the de facto standards for future aging research funding — both federal and private. Aligning your research to those metrics now, before they're formally required, positions you for the next wave of funding.

Track ARPA-H's broader portfolio. The agency has committed significant resources to aging-adjacent areas, including chronic disease prevention and health data infrastructure. PROSPR is the flagship, but it won't be the last program. ARPA-H program managers rotate through focus areas, and Andrew Brack's team will likely seed follow-on programs as PROSPR results emerge.

For clinical research organizations and academic medical centers not in the current cohort, the VITAL-H trial design offers a template. Multi-site trials testing repurposed FDA-approved drugs against composite functional endpoints — with wearable technology for monitoring — represent a model that NIH, the VA, and private funders are all likely to replicate.

And for the biotech companies watching from the sidelines: PROSPR just proved that ARPA-H will write eight-figure contracts to commercial longevity companies with credible clinical programs. The barrier to entry isn't a university affiliation or a decades-long publication record. It's a drug candidate with safety data and a trial design that can deliver results on an aggressive timeline.

The federal government has spent decades funding research into individual diseases of aging while carefully avoiding the suggestion that aging itself might be treatable. PROSPR breaks that pattern. Whether any of these five drugs actually slows human aging remains an open question — but the fact that the question is now being asked with $144 million in milestone-driven contracts behind it changes the landscape for every researcher, funder, and company in the field.

If you're working in healthspan research, longevity therapeutics, or aging-related clinical science, Granted can help you identify federal and foundation funding opportunities aligned with your program — including upcoming ARPA-H solicitations as they're announced.